Skip to main content
Fig. 1 | BMC Infectious Diseases

Fig. 1

From: Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients

Fig. 1

Cumulative probabilities of virological failure (Panel a) and of treatment failure (Panel b) after switch to a rilpivirine- and or to an integrase inhibitor (InSTI)-based regimen. RPV: rilpivirine; InSTI: integrase strand transfer inhibitor; FTC: emtricitabine; TDF: ftenofovir disoproxil fumarate

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us